Genmab A/S (GMAB)
| Market Cap | 28.72B |
| Revenue (ttm) | 1.71B |
| Net Income (ttm) | 886.51M |
| Shares Out | 653.56M |
| EPS (ttm) | 1.34 |
| PE Ratio | 33.15 |
| Forward PE | 101.01 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $44.58 |
| Previous Close | $44.02 |
| Change ($) | 0.56 |
| Change (%) | 1.27% |
| Day's Open | 43.96 |
| Day's Range | 43.96 - 44.92 |
| Day's Volume | 694,695 |
| 52-Week Range | 30.10 - 44.92 |
Company Announcement
Media Release
Media Release Copenhagen, Denmark, June 1 , 2021 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer , Anthony Pagano and C hief D evelopment O fficer , Judith Klimovsky , wil...
Company Announcement
Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to Genmab A/S (NASDAQ: GMAB) and its partn...
COPENHAGEN, Denmark; May 21, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the d...
Company Announcement
May 5 , 20 21 ; Copenhagen, Denmark ;
Company Announcement
Company Announcement
Company Announcement
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclero...
Media Release Copenhagen, Denmark, March 29, 2021
Company Announcement
Company Announcement
Company Announcement
Introduction
Company Announcement
Company Announcement
Company Announcement
Company Announcement
Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Billion Marke...
Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the treatment of...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food a...
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...
Company Announcement
Company Announcement
Company Announcement
Company Announcement
Media Release Copenhagen, Denmark, January 6, 2021
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
Media Release COPENHAGEN, Denmark, Jan. 04, 2021
Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast.
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for tr... [Read more...]
| Industry Biotechnology | Founded 1999 |
| CEO Jan van de Winkel | Employees 871 |
| Stock Exchange NASDAQ | Ticker Symbol GMAB |
Financial Performance
In 2020, Genmab A/S's revenue was 10.11 billion, an increase of 88.43% compared to the previous year's 5.37 billion. Earnings were 4.76 billion, an increase of 119.67%.
Analyst Forecasts
According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.21, which is a decrease of -5.32% from the latest price.